Jun 22, 2020
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 07, 2020
Agenus First Quarter Results and Update
Apr 22, 2020
Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent
Apr 14, 2020
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
Mar 26, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
Mar 09, 2020
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
Feb 20, 2020
Compugen Reports Fourth Quarter and Full Year 2019 Results
Feb 07, 2020
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-oncology Symposium
Feb 04, 2020
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
Jan 29, 2020
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
Jan 09, 2020
Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones
Nov 06, 2019
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
Nov 05, 2019
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
Nov 04, 2019
Compugen Announces FDA Clearance of IND Application for COM902
Jul 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Jan 22, 2019
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
Nov 13, 2018
Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy